Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.

Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T

Open source

DOI: 10.1038/s41591-022-01933-w
Published: 2022 Sep
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-022-01933-w,
  title = {Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.},
  author = {Peters S and Dziadziuszko R and Morabito A and Felip E and Gadgeel SM and Cheema P and Cobo M and Andric Z and Barrios CH and Yamaguchi M and Dansin E and Danchaivijitr P and Johnson M and Novello S and Mathisen MS and Shagan SM and Schleifman E and Wang J and Yan M and Mocci S and Voong D and Fabrizio DA and Shames DS and Riehl T and Gandara DR and Mok T},
  year = {2022},
  journal = {Nature medicine},
  doi = {10.1038/s41591-022-01933-w},
  url = {https://doi.org/10.1038/s41591-022-01933-w}
}

RIS

TY  - JOUR
TI  - Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
AU  - Peters S
AU  - Dziadziuszko R
AU  - Morabito A
AU  - Felip E
AU  - Gadgeel SM
AU  - Cheema P
AU  - Cobo M
AU  - Andric Z
AU  - Barrios CH
AU  - Yamaguchi M
AU  - Dansin E
AU  - Danchaivijitr P
AU  - Johnson M
AU  - Novello S
AU  - Mathisen MS
AU  - Shagan SM
AU  - Schleifman E
AU  - Wang J
AU  - Yan M
AU  - Mocci S
AU  - Voong D
AU  - Fabrizio DA
AU  - Shames DS
AU  - Riehl T
AU  - Gandara DR
AU  - Mok T
PY  - 2022
JO  - Nature medicine
DO  - 10.1038/s41591-022-01933-w
UR  - https://doi.org/10.1038/s41591-022-01933-w
ER  -

APA

S, P., R, D., A, M., E, F., SM, G., P, C., M, C., Z, A., CH, B., M, Y., E, D., P, D., M, J., S, N., MS, M., SM, S., E, S., J, W., M, Y., S, M., D, V., DA, F., DS, S., T, R., DR, G., & T, M. (2022). Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.. Nature medicine. https://doi.org/10.1038/s41591-022-01933-w

Source records

pubmed · retrieved 2026-09-27T11:03:40.404Z